swiss medicaXXI century S.A.When Crohn’s disease continues to affect daily life despite biologic treatment, patients often look for what else may be available. Stem cell therapy for Crohn’s disease is one of the regenerative options now being studied—both as an investigational approach for refractory disease and as a specific treatment for complex perianal fistulas. The field has moved meaningfully over the past few years, and a clearer picture of who may benefit and what realistic outcomes look like has begun to take shape.
Why Crohn’s Disease Can Be Difficult to Manage
Crohn’s is a relapsing-remitting inflammatory bowel disease (IBD) that often requires lifelong management. Even with modern biologic therapy, a meaningful portion of patients continue to experience symptoms, ongoing inflammation, or complications such as fistulas and strictures—which is why interest in additional options remains high.
Crohn’s Disease Is More Than Digestive Symptoms
The condition is often described in terms of abdominal pain, diarrhea, and weight loss, but extraintestinal manifestations are common—joint inflammation, skin lesions, eye involvement, and persistent fatigue may all affect daily functioning. Because these symptoms do not always reflect the level of bowel inflammation, “feeling better” and “being in remission” are not always the same thing.
Why Symptoms, Inflammation, and Tissue Damage Are Different
A patient may feel reasonably well while inflammation continues silently, gradually causing strictures or penetrating disease. This is the rationale for measuring inflammation through endoscopy, imaging (MRI enterography, intestinal ultrasound), and biomarkers such as fecal calprotectin and CRP, rather than relying on symptom relief alone. Doctors are increasingly aiming for healing of the entire bowel wall, not just the inner lining, because it may be a more meaningful long-term treatment goal.
Why Perianal Fistulas Require Special Attention
Perianal fistulas are abnormal tracts that can form between the anal canal or rectum and the skin near the anus. They are developed in 13–39% of patients with Crohn’s disease and often require a different treatment approach than the underlying luminal inflammation.
Standard care typically combines seton placement with anti-TNF therapy (infliximab, adalimumab), which achieves wound healing in 40–70% of cases but does not always close the fistula tract permanently. This is one of the main areas where stem cell therapy for Crohn’s is being actively investigated, with several clinical programs focused specifically on refractory perianal fistulas.
What Is the Most Effective Treatment for Crohn’s Disease?
There is no single “most effective” treatment for Crohn’s disease—the right approach depends on where the disease is located, how active it is, and whether complications are present. Treatment plans are usually built around the patient’s specific disease pattern and history rather than a fixed protocol.
The Best Treatment Depends on Disease Severity and Location
Mild conditions may be managed with corticosteroids and conventional immunomodulators (azathioprine, methotrexate).
A moderate-to-severe condition is typically treated with biologics—including anti-TNFs (infliximab, adalimumab), anti-integrins (vedolizumab), or IL-12/23 and IL-23 inhibitors (ustekinumab, risankizumab). Surgery is reserved for strictures, refractory inflammation, or complications. Each line of treatment is chosen based on disease behavior, location, and prior response.
For inflammatory flares, corticosteroids may be used to induce remission in appropriate cases. Because corticosteroids are not a long-term maintenance strategy, gastroenterologists usually aim to reduce steroid exposure once control is achieved. Immunomodulators such as azathioprine, mercaptopurine, or methotrexate may be considered for steroid-sparing or maintenance strategies in selected clinical situations, but they do not work as immediate symptom-relief medicines.
Why Achieving and Maintaining Remission Is the Main Goal
The treatment goal in Crohn’s disease is not just symptom control but sustained remission—combining clinical, biochemical, and endoscopic improvement. Achieving remission reduces the risk of bowel damage, surgery, and hospitalization over time. Maintaining it usually requires long-term medication and close monitoring, even in patients who feel well.
Where Stem Cell Therapy May Fit Into Crohn’s Disease Care
Mesenchymal stem cell therapy for Crohn’s disease is not positioned as a replacement for biologics such as Humira (adalimumab), Stelara (ustekinumab), Skyrizi (risankizumab), or Remicade (infliximab) nor as an alternative to surgery.
Stem cell therapy procedure are studied as a complementary option, particularly for patients with refractory disease or complex perianal fistulas that have not responded to standard therapy. Whether stem cell therapy for Crohn’s disease can help in a specific case is decided after detailed review of the patient’s previous treatment history, current disease activity, and goals.
How Stem Cell Therapy May Support Patients With Crohn’s Disease
The biological rationale for using stem cells in Crohn’s disease centers on two related effects: modulating the immune response that drives chronic inflammation and supporting tissue repair where damage has already occurred—particularly in fistula tracts.
What Current Research Suggests
Stem cell therapy studies and clinical research have expanded substantially in the past decade.
A Crohn’s disease landscape analysis of 170 stem cell clinical trial reports shows that mesenchymal stem cells (MSCs) account for more than 70% of cell types studied, with most trials focused on refractory perianal fistulas.
Immune Modulation and Inflammation Control Under Investigation
Stem cell therapies for inflammatory bowel disease are believed to act primarily through paracrine signaling—releasing growth factors such as VEGF and TGF-β, anti-inflammatory cytokines, and extracellular vesicles (exosomes) that influence immune cell behavior in nearby tissue.
Tissue Repair and Perianal Fistula Treatment
For complex perianal fistulas in Crohn’s disease, locally administered cell therapy is the most-developed application. Stem cell clinical trials in Crohn’s disease show that, over six months of follow-up, complete closure of refractory fistula tracts is achieved in 60% of cases with reduced local inflammation on histology.
Another stem cell research for Crohn’s disease is currently evaluating allogeneic adipose-derived stem cells for the same indication after conventional treatment has failed.
What Stem Cell Therapy Cannot Promise
Cell-based therapy is studied as a complementary option in Crohn’s disease, working alongside ongoing gastroenterology care rather than replacing it. It is not framed as a cure or as a way to discontinue biologics or surgery when these are clinically indicated. Clinics that present stem cell therapy for inflammatory bowel disease as a definitive cure should be approached with skepticism.
What Improvements May Look Like in Daily Life
Reported improvements after stem cell therapy for IBD and Crohn’s disease tend to develop gradually, measured against the patient’s own baseline rather than against a hypothetical “healthy” state.
Possible outcomes documented in clinical work include:
- reduced symptom burden;
- improved quality of life;
- support for perianal fistula healing;
- reduced disease-related discomfort;
- improved participation in daily activities;
- a complementary effect alongside ongoing standard treatment.
Why Results Can Differ Between Patients
The clinical response depends on disease severity, location, duration, prior treatment history, presence of complications, and how much functional tissue is preserved at the time of treatment. This is why the medical evaluation before treatment matters — it helps frame what may be realistic for the specific case.
Patient Story: Living With Crohn’s Disease Before and After Treatment
Armando is a patient from the western United States who traveled to Swiss Medica, in Belgrade after researching regenerative therapy options for his chronic inflammation.
“My research led me to this clinic, and the results have exceeded my expectations. Within days of starting stem cell therapy for Crohn’s disease, I noticed more energy, better sleep, and less joint and back pain. I know further improvements may take time, but I already feel the treatment is making a real difference. The care here is holistic and supportive, and I felt looked after throughout the entire process.”
Arnaldo’s testimonial reflects the early period after the initial infusions; the more substantial regenerative changes are typically assessed over the months that follow treatment.
You can explore more stories from patients on Swiss Medica’s official YouTube channel.
What This Experience Can and Cannot Tell Us
Armando’s experience shows that even when living with a complex condition like Crohn’s disease, it is possible to seek new options, stay proactive, and find approaches that support overall well-being. His story reflects not only physical changes but also the importance of feeling heard, supported, and actively involved in one’s own care journey.
At the same time, every patient’s path is unique. While no treatment can guarantee specific results, a comprehensive and individualized approach offers the opportunity to improve quality of life and move forward with greater confidence and hope.
Who May Be Considered for Crohn’s Stem Cell Treatment?
At Swiss Medica, candidacy for regenerative care is based on the specific disease pattern, prior treatment response, and overall medical picture, rather than a general checklist. The review happens before any program is proposed.
Patients With Refractory or Complicated Crohn’s Disease
The most-discussed candidates for stem cell treatment for Crohn’s disease are patients whose disease has not responded adequately to multiple lines of biologic therapy or who continue to experience active inflammation despite ongoing treatment. Patients with stricturing or penetrating complications may also be discussed individually, depending on the specifics of their imaging and surgical history.
Patients With Complex Perianal Fistulas
Complex perianal fistulas resistant to anti-TNF therapy and surgical seton placement are one of the most studied indications for locally administered stem cell therapy in Crohn’s disease. Eligibility typically requires controlled luminal disease, defined imaging criteria for the fistula anatomy, and prior failure of conventional treatment.
Interested in stem cell therapy?
Book a free online consultation with a Swiss Medica regenerative medicine specialist to discuss your condition and determine your suitability for therapy.
Medical Advisor, Swiss Medica doctor
What Happens During Treatment at Swiss Medica?
For patients traveling to Belgrade, the application process begins with a remote review of medical records and continues through several distinct stages once the patient arrives.
Medical Records and Tests Swiss Medica Reviews
At Swiss Medica, before any stem cell treatment for Crohn’s disease is offered, the medical team reviews a defined set of records the patient submits ahead of arrival. These typically include:
- recent colonoscopy reports with biopsies;
- pelvic MRI when perianal disease is present;
- intestinal MRI enterography or CT enterography;
- pathology findings;
- biologic treatment history and response;
- previous surgical history;
- current medications and recent laboratory work.
The pre-arrival review shapes the initial program proposal that the patient receives before traveling.
Personalized Treatment Planning Based on Disease Activity and Goals
The proposed program depends on whether the patient has predominantly luminal disease, perianal involvement, or both, and on the patient’s own goals—symptom control, healing of a specific fistula, or supporting remission alongside biologic therapy. The medical team discusses what is realistic given the specific case before any treatment begins.
After arrival, the plan is reviewed again during the in-person assessment. At this stage, the medical team may confirm the proposed program or adjust it if the patient’s current condition, symptoms, laboratory findings, or safety profile suggest that additional tests or changes are needed
Stem Cell Therapy and Supportive Care
Before administration, the cell product is prepared in the in-house laboratory, with testing for identity, viability, sterility, and contamination. Stem cell therapies for Crohn’s disease are most often delivered by:
- Intravenous infusion: generally used for active luminal disease to provide systemic effects;
- local administration, such as enemas or suppositories: considered in selected cases to target affected areas directly.
Supportive therapies that may accompany cell therapy depend on the individual case and are discussed before treatment begins. They are not added as a fixed package and should be selected only after the medical team reviews the patient’s diagnosis, current disease activity, laboratory findings, previous treatment history, and safety profile.
Depending on the case, supportive care may include the following:
- Intracellular Metabolism Recovery (IMR), including intravenous drips with vitamins and antioxidants, when additional metabolic and recovery support is considered appropriate.
- Plasmapheresis, when the medical team considers that additional support for inflammatory, immune-related, or metabolic balance may be relevant.
- General supportive therapies aimed at helping the patient tolerate the program better, maintain energy, and support recovery during the in-clinic stage.
Supportive care is not presented as a stand-alone treatment for Crohn’s disease and does not replace standard gastroenterology management. Its role is to complement the regenerative part of the program when medically appropriate and to support the patient’s overall condition.
You can explore stem cell therapy step-by-step—from initial remote consultationand arrival to medical evaluation, treatment, and follow-up.
Follow-Up
Follow-up recommendations are discussed individually with the patient before they return home. Patients may be guided through what to expect from stem cell therapy and advised to repeat relevant tests in the coming months so that changes can be compared to their own baseline. And a free follow-up in-clinic visit is scheduled during this remote monitoring.
Safety, Side Effects, and Questions to Ask Before Treatment
Safety in stem cell treatment for Crohn’s disease depends on the quality of the cell product, careful patient selection, and clear answers to the right questions before starting any program.
Possible Side Effects and Treatment Risks
In published clinical trials, reported side effects of MSC therapy in Crohn’s disease have generally been mild and short-lived. They may include:
- local discomfort or swelling at the injection site for perianal procedures;
- short-term low-grade fever after IV administration;
- transient fatigue;
- mild general discomfort during recovery.
Serious adverse events have been uncommon when cells are prepared under proper laboratory conditions and administered by experienced clinicians.
Read about stem cell therapy safety and side effects, the published adverse-event data, and the laboratory and procedural controls used to keep risks low.
Why Infection Screening Is Important in Crohn’s Disease
Patients with Crohn’s disease are often on immunosuppressive or biologic therapy, which raises the importance of careful pre-treatment screening for latent tuberculosis, hepatitis B and C, HIV, and active infection at planned injection sites in perianal cases. Routine screening before cell-based therapy reduces the risk of complications related to the patient’s underlying immune status.
Questions Patients Should Ask Before Choosing a Clinic
Before agreeing to any cell-based treatment for Crohn’s disease, useful questions to ask include:
- What is the cell source, and how is the product prepared and tested?
- What route of administration is being proposed, and why?
- Has my specific disease pattern been treated with this protocol before?
- What follow-up is planned, and how will outcomes be measured?
- What does the clinic say about cases that did not respond?
- What ongoing care will I need after the program ends?
Honest answers to these questions tell more about a clinic than headline marketing claims.
Cost of Stem Cell Treatment for Crohn’s Disease
At Swiss Medica, costs typically fall within a €7,000–€45,000* range, with the exact figure shaped by disease severity, presence of complications, and the structure of the proposed program.
The stem cell therapy cost varies meaningfully between countries and clinics, and a personalized estimate prepared after medical record review tends to describe what the patient will actually receive far more accurately than a flat package price.
* Prices are indicative and based on 2026 estimates; they may vary depending on disease severity, presence of perianal complications, and required cell quantity.
Why Treatment Costs Depend on the Individual Case
Several variables shape the final figure for any Crohn’s regenerative program. These are discussed openly with the patient before any commitment and may include:
- disease severity and duration;
- presence of fistulas or other complications;
- diagnostic testing required (MRI, colonoscopy, biomarkers);
- cell source and preparation;
- route and number of cell administrations;
- program length;
- supportive therapies included in the program;
- accommodation and length of stay;
Why a Personalized Cost Estimate Is More Reliable Than a Flat Price
Because Crohn’s disease varies meaningfully from patient to patient — from mild luminal inflammation to refractory perianal fistulas after multiple failed biologics — a quoted figure produced after record review tends to describe what the patient will actually receive far more accurately than a generic package price. The stem cell therapy cost for Crohn’s disease is shaped by what the case actually requires.
What May Be Included in the Treatment Program
A stem cell therapy for Crohn’s disease at Swiss Medica is planned individually after reviewing the patient’s diagnosis, current symptoms, previous therapies, medical history, and overall health status.
While regenerative therapy is the main part of the program, its effectiveness can depend on many factors, including the level of inflammation, nutritional status, immune function, and the body’s overall ability to recover.
For this reason, stem cell therapy for Crohn’s is often combined with supportive medical measures designed to create more favorable conditions for regeneration and to help the body respond to treatment more effectively.
| Anti-inflammatory and immune-supportive therapy | Supportive therapies may be used to help reduce systemic inflammatory burden and support immune balance. This can be especially relevant for patients with chronic inflammation, fatigue, or recurrent flare-related stress on the body. |
| Nutritional and metabolic support | Crohn’s disease may affect nutrient absorption and contribute to weight loss, weakness, anemia, or deficiencies. Nutritional support may help restore missing nutrients, improve tolerance, and support the body during recovery. |
| Detoxification and organ-supportive procedures | When appropriate, supportive procedures may be used to help the body process inflammatory by-products and treatment-related metabolic load. These procedures are selected according to the patient’s test results and general condition. |
Why Patients Choose Swiss Medica for Crohn’s Disease Treatment
The Swiss Medica clinic in Belgrade has hosted patients from 70+ countries for regenerative care across a range of autoimmune and chronic conditions, including refractory Crohn’s disease.
Individual Medical Assessment Before Treatment
Every Crohn’s case at Swiss Medica is reviewed individually, with the program adapted to the patient’s disease pattern; fistula anatomy, where present; prior treatment response; and personal goals—rather than applied as a fixed template. Expectations are discussed openly with the patient before treatment begins.
In-House Cell Processing and Quality Standards
Cell preparation is handled through Swiss Medica’s in-house laboratory processes, which helps the medical team maintain oversight of the biomedical products used in therapy. Quality control focuses on:
- product identity,
- viability,
- sterility.
These controls matter because safety in regenerative care depends not only on the procedure but also on the way the cell product is prepared and checked.
Structured Follow-Up After the Stay
Treatment does not end when the patient leaves the clinic; our team continues to support the patient through structured remote follow-up. This continued contact is part of our approach: patient may be advised to repeat relevant tests over the following months, such as inflammatory biomarkers or imaging, so that progress can be compared with the pre-treatment baseline.
Swiss Medica also offers a free follow-up visit in 3-6 months. During this visit, the patient can discuss recovery, ask questions about the next steps, and receive guidance on how to track changes over time.
International Patient Support in Serbia
International patients are coordinated by Swiss Medica’s English-speaking team from the first inquiry through the months that follow treatment. Travel and accommodation, airport transfers, meals, and translation are organized in advance. Dietary requirements are also met, as many Crohn’s patients have specific dietary needs.
Discover more about Swiss Medica, including the condition we treat, how our regenerative medicine strategy operates, and the reasons why patients from all over the world choose our clinic.
Speak With a Medical Advisor About Crohn’s Disease Treatment Options
For patients who want to understand whether regenerative care may fit alongside their current Crohn’s treatment, the next step is a confidential video consultation at no charge.
Get a free online consultation
Send us your recent colonoscopy reports, imaging studies, and a brief treatment history, and the medical team will review the case, discuss what realistic outcomes might look like for the specific disease pattern, and explain how stem cell treatment for Crohn’s disease has been investigated for similar profiles. Use the form below or submit your records directly — every conversation is handled with full discretion.
Medical Advisor, Swiss Medica doctor
FAQ
1. What is the most effective treatment for Crohn’s disease?
There is no single most effective treatment. The right approach depends on disease severity, location, and complications. Biologics such as anti-TNFs and anti-IL-23 agents remain the standard for moderate-to-severe disease. Stem cell therapy for Crohn’s may be considered as a supportive option in selected cases where standard treatments are not sufficient, following individual medical evaluation.
2. Can stem cell treatment cure Crohn’s disease?
No. Cell-based therapy is not a cure. It is studied as a way to modulate the immune response and support tissue healing—particularly in fistulas—alongside standard gastroenterology care. Remission, when it occurs, generally still requires ongoing management.
3. How does stem cell therapy work for Crohn’s disease?
The proposed mechanism is primarily immunomodulatory. Mesenchymal stem cells release growth factors and anti-inflammatory signals that may reduce local inflammation and support tissue repair, particularly in perianal fistula tracts. Most of the evidence is still early-phase.
4. Can stem cell therapy help Crohn’s fistulas?
Complex perianal fistulas are the most-developed indication for cell-based therapy in Crohn’s disease. Adipose-derived MSCs previously received European approval for this use, and recent Phase II work with MSC-derived exosomes reported high closure rates in refractory cases.
5. Who may be a candidate for Crohn’s stem cell treatment?
Patients with refractory disease, complex perianal fistulas not responding to standard care, or specific complications discussed individually with the medical team.
6. Is stem cell treatment for Crohn’s disease safe?
In published trials, reported side effects have generally been mild and short-lived. Serious adverse events have been uncommon when cells are prepared under proper laboratory standards. Pre-treatment screening for infections is particularly important in Crohn’s patients on immunosuppressive therapy.
7. Does stem cell therapy for Crohn’s replace biologics or surgery?
No. It is studied as a complement to standard treatment, not as a replacement. Biologics and surgery remain the established options for moderate-to-severe Crohn’s disease and its complications. Discontinuing a working biologic on the assumption that cell therapy will replace it is not supported by current data.
8. What medical records are needed before consultation?
Most consultations begin with recent colonoscopy reports, pelvic MRI for perianal disease, MRI or CT enterography, pathology findings, biologic treatment history, and surgical history. Additional records may be requested if the case requires clarification.
9. How long does it take to notice changes after treatment?
Changes after cell-based treatment for Crohn’s disease tend to develop gradually rather than immediately. Some patients report early subjective changes within the first weeks; objective changes — fistula closure, reduced inflammation markers — are typically assessed over the months that follow treatment.
10. How much does stem cell treatment for Crohn’s disease cost?
At Swiss Medica, programs typically range from €7,000 to €45,000* depending on disease severity, fistula complexity, the type of program, cell quantity, administration route, diagnostics, supportive care, and length of stay. Prices in the USA, Switzerland, and the UK are generally higher than in Serbia due to operational and regulatory expenses.
* Prices are indicative and based on 2026 estimates; they may vary depending on disease severity, presence of perianal complications, and required cell quantity.
List of References:
Gao J, Liu Y, Xia T, et al. Mapping the landscape and future directions of stem cell therapy for inflammatory bowel disease. Stem Cell Research & Therapy. 2026;17(1). https://doi.org/10.1186/s13287-026-04999-2
Patel JC, Shukla M, Shukla M. From bench to bedside: translating mesenchymal stem cell therapies through preclinical and clinical evidence. Frontiers in Bioengineering and Biotechnology. 2025;13:1639439. https://doi.org/10.3389/fbioe.2025.1639439
Hadizadeh A, Akbari Asbagh R, Heirani-Tabasi A, et al. Localized Administration of Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Refractory Perianal Fistula in Patients With Crohn’s Disease: A Phase II Clinical Trial. Diseases of the Colon and Rectum. 2024;67(12):1564-1575. https://doi.org/10.1097/DCR.0000000000003502
Buscail E, Gilletta de Saint Joseph C, Lebrin M, et al. Rationale and design of the AlloFIST trial: a phase I/IIa study to evaluate dose escalation of allogeneic adipose-derived stroma/stem cells for the treatment of Crohn’s fistula. BMJ Open. 2025;15(12):e104517. https://doi.org/10.1136/bmjopen-2025-104517
Medical Advisor, Swiss Medica doctor
